6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl)-1-methyl-2-naphthamide | 337522-79-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl)-1-methyl-2-naphthamide
• 英文别名: 6-[1-hydroxy-1-(1H-imidazol-5-yl)-2-methylpropyl]-1-methylnaphthalene-2-carboxamide
• CAS: 337522-79-9
• 化学式: C₁₉H₂₁N₃O₂
• 分子量: 323.395
• InChiKey: LRHLIQGXFDBFIL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  92
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  6-[1-hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl)-1-methyl-2-naphthamide 生成 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl)-1-methyl-2-naphthamide
  参考文献：
  名称：

  Imidazol-4-ylmehanols and their use as inhibitors of steroid C17-20 lyase

  摘要：

  Imidazol-4-ylmethanols及其用于预防和治疗原发性肿瘤、肿瘤转移和复发、伴随肿瘤的各种症状、前列腺肥大、男性化、多毛症、男性型脱发、性早熟、子宫内膜异位症、子宫肌瘤、乳腺病和多囊卵巢综合征的用途被披露。

  公开号：

  US06649643B1

文献信息

• IMIDAZOL-4-YLMETHANOLS USED AS INHIBITORS OF STEROID C17-20 LYASE
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1222174B1

  公开（公告）日：2009-05-27
• PHARMACOPHORES, COMPOUNDS AND METHODS HAVING APPLICATION IN THE TREATMENT OF CANCER THROUGH INHIBITION OF CYP17A1 AND CYP19A1
  申请人：Mangosuthu University Of Technology

  公开号：EP3365819A2

  公开（公告）日：2018-08-29
• US6649643B1
  申请人：——

  公开号：US6649643B1

  公开（公告）日：2003-11-18
• [EN] IMIDAZOL-4-YLMETHANOLS USE AS INHIBITORS OF STEROID C17-20 LYASE<br/>[FR] UTILISATION D'IMIDAZOL-4-YLMETHANOLS EN TANT QU'INHIBITEURS DE LYASE C17-20 STEROIDIENNE
  申请人：TAKEDA CHEMICAL INDUSTRIES LTD

  公开号：WO2001030762A1

  公开（公告）日：2001-05-03

  The present invention provides a compound represented by formula (I), wherein R is a hydrogen atom or a protecting group, R1 is a lower alkyl group or a cyclic alkyl group, R2 is a group represented by formula (1), (wherein a ring A1 is a 5- or 6-membered ring containing an oxygen atom optionally having substituents, and a ring A2 and a ring A3 may have substituents), a group represented by formula (2), (wherein the ring B1 is a 5- or 6-membered ring containing an oxygen atom optionally having substituents and a ring B2 and a ring B3 may have substituents) or a group of formula (3), (wherein each of R?3 and R5¿ is a hydrogen atom, a lower alkyl group optionally having substituents, a hydroxyl group optionally having substituents, a thiol group optionally having substituents, an amino group optionally having substituents, an acyl group or a halogen atom, R4 is an aromatic hydrocarbon group optionally having substituents, a heterocyclic group optionally having substituents or a carbamoyl group optionally having substituents, R6 is an optionally halogenated lower alkyl group and n is an integer of 0 to 3), or a salt thereof, which has an inhibitory activity of steroid C¿17-20?-lyase and are useful for preventing and treating a mammal suffering from, for example, primary tumor, its metastasis and recurrence thereof, and various symptoms accompanied with these cancer, various diseases such as prostatic hypertrophy, virilism, hirsutism, male pattern alopecia, precocious puberty, endometriosis, uterus myoma, mastopathy, polycystic ovary syndrome, etc.
• [EN] PHARMACOPHORES, COMPOUNDS AND METHODS HAVING APPLICATION IN THE TREATMENT OF CANCER THROUGH INHIBITION OF CYP17A1 AND CYP19A1<br/>[FR] PHARMACOPHORES, COMPOSÉS ET PROCÉDÉS AYANT UNE APPLICATION DANS LE TRAITEMENT DU CANCER PAR INHIBITION DE CYP17A1 ET CYP19A1
  申请人：MANGOSUTHU UNIV OF TECH

  公开号：WO2017070718A1

  公开（公告）日：2017-04-27

  The invention provides compounds for use as medicaments, which act by inhibiting CYP17A1 and CYP19A1 enzymes. The compounds have particular application in the treatment of cancer especially prostate cancer and breast cancer. The compounds have the formula: [Chem. 1] wherein: R is independently selected from the group consisting of optionally substituted arylamide; optionally substituted alkylarylamide; optionally substituted aryl carboxamide; optionally substituted cyanopiperidine; optionally substituted oxopiperidine; optionally substituted N-(pyridin-3-yl); optionally substituted pyridin-3-yl; optionally substituted pyrazole-4-carboxamide; optionally substituted pyrimidin-4-ylcarboxamide; optionally substituted pyrimidin-4-ylcarboxamide; optionally substituted 1H-pyrrol-2-ylcarboxamide; optionally substituted morpholin carboxamide; optionally substituted 1H-indazol-3-ylcarboxamide; optionally substituted 5-cyanopiperidin-3-ylcarboxamide; optionally substituted quinolin-7-yl; optionally substituted pyrazin-2-ylcarboxamide; optionally substituted 1H-1,3-benzodiazole-6-carboxamide; and optionally substituted 3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-ylcarboxamide; Each R1, R2, R3, R4, R5 is independently selected from the group consisting of H; OH; a halogen atom; OCH3; and NH2; and X is independently selected from the group consisting of O, H and OH. Some of the compounds are claimed per se and the invention also encompasses pharmaceutically acceptable salts, solvates, hydrates, primary metabolites and prodrugs thereof.